EN
Patient-first cell therapy innovation
Pipelines
China Global U.S.A
TCR/CAR-T
Product
Indication
Description
E202
Cervical cancer
Next generation TCR-T armored with checkpoint blockade
N201
synovial sarcoma, lung cancer, and other solid tumors
Next generation TCR-T armored with checkpoint blockade
A103
Ovarian, Cervical, and endometrial cancer
First in class CAR-T product
L200s
NPC and NKT lymphoma
Next generation TCR-T armored with checkpoint blockade
U101
Lung, liver and Colorectal cancer
Next generation NK armored with checkpoint blockade
H101
DIPG
Tumor cancer vaccine product
I301
Glioma
Next generation CAR-T armored with tumor microenvironment reconditioning agent

Copyright © 2019 TCR CURE Biopharma Technology Co., Ltd Powered by vancheer
About TCRCure
Research and Development
Product and Cinical trial
News and Media
Recruitment

Copyright © 2019 TCR CURE Biopharma Technology Co., Ltd Powered by vancheer